Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5644_Библиотеки_им_академика_М_И_Перельмана
.pdf
References 345
https://t.me/med1917
148 Huang, H., Wang, Y., Kandpal, M. et al. (2020). FTO-dependent N
(6)-methyladenosine modications inhibit ovarian cancer stem cell self-renewal
by blocking cAMP signaling. Cancer Res. 80: 3200–3214.
149 Malacrida, A. et al. (2020). 3D proteome-wide scale screening and activity eval-
uation of a new ALKBH5 inhibitor in U87 glioblastoma cell line. Bioorg. Med.
Chem. 28: 115300.
150 Yuan, Y., Rivara, M., Di Domizio, A. et al. (2021). ALKBH5 suppresses tumor
progression via an m6A-dependent epigenetic silencing of pre-miR-181b-1/YAP
signaling axis in osteosarcoma. Cell Death Dis. 12: 60.
151 Wei, C. et al. (2022). Pan-Cancer analysis shows that ALKBH5 is a poten-
tial prognostic and immunotherapeutic biomarker for multiple cancer types
including gliomas. Front. Immunol. 13.
152 Qu, J., Yan, H., Hou, Y. et al. (2022). RNA demethylase ALKBH5 in cancer:
from mechanisms to therapeutic potential. J. Hematol. Oncol. 15: 8.
153 Hess, M.E., Hess, S., Meyer, K.D. et al. (2013). The fat mass and obesity associ-
ated gene (FTO) regulates activity of the dopaminergic midbrain circuitry. Nat.
Neurosci. 16: 1042–1048.
154 Chang, R., Huang, Z., Zhao, S. et al. (2022). Emerging roles of FTO in
neuropsychiatric disorders. Biomed Res. Int. 2022: 2677312.
155 Wang, B., Fang, X., Sun, X. et al. (2021). m(6)A demethylase ALKBH5 sup-
presses proliferation and migration of enteric neural crest cells by regulating
TAGLN in Hirschsprung’s disease. Life Sci. 278: 119577.
156 Bego, T.,ˇCauševi´c, A., Duji´c, T. et al. (2019). Association of FTO gene variant
(rs8050136) with type 2 diabetes and markers of obesity, glycaemic control and
inammation. J. Med. Biochem. 38: 153–163.
157 Daoud, H., Zhang, F.M.M. et al. (2016). Identication of a pathogenic FTO
mutation by next-generation sequencing in a newborn with growth retardation
and developmental delay. J. Med. Genet. 53: 200–207.
158 Kim, H., Lee, Y. , Kim, S.M. et al. (2021). RNA demethylation by FTO stabilizes
the FOXJ1 mRNA for proper motile ciliogenesis. Dev. Cell 56: 1118–1130. e1116.
159 Azzam, S.K., Alsafar, H., and Sajini, A.A. (2022). FTO m6A demethylase in obe-
sity and cancer: implications and underlying molecular mechanisms. Int. J. Mol.
Sci. 23.
160 Su, R., Dong, L., Li, Y. et al. (2020). Targeting FTO suppresses cancer stem cell
maintenance and immune evasion. Cancer Cell 38: 79–96.e11.
161 Huang, Y., Su, R., Sheng, Y. et al. (2019). Small-molecule targeting of oncogenic
FTO demethylase in acute myeloid leukemia. Cancer Cell 35: 677–691.e610.
162 Sun, K., Du, Y. , Hou, Y. et al. (2021). Saikosaponin D exhibits anti-leukemic
activity by targeting FTO/m(6)A signaling. Theranostics 11: 5831–5846.
163 Qin, B., Bai, Q., Yan, D. et al. (2022). Discovery of novel mRNA demethylase
FTO inhibitors against esophageal cancer. J. Enzyme Inhib. Med. Chem. 37:
1995–2003.
164 Xie, G., Wu, X.N., Ling, Y. et al. (2022). A novel inhibitor of
N6-methyladenosine demethylase FTO induces mRNA methylation and shows
anti-cancer activities. Acta Pharm. Sin. B 12: 853–866.
346 12 Drugging the Epitranscriptome
https://t.me/med1917
165 Takahashi, H., Hase, H., Yoshida, T. et al. (2022). Discovery of two novel
ALKBH5 selective inhibitors that exhibit uncompetitive or competitive type
and suppress the growth activity of glioblastoma multiforme. Chem. Biol. Drug
Design 100: 1–12.
166 Selberg, S., Seli, N., Kankuri, E., and Karelson, M. (2021). Rational design of
novel anticancer small-molecule RNA m6A demethylase ALKBH5 inhibitors.
ACS Omega 6: 13310–13320.
167 Dai, Q., Zhang, L.S., Sun, H.L. et al. (2023). Quantitative sequencing using
BID-seq uncovers abundant pseudouridines in mammalian mRNA at base
resolution. Nat. Biotechnol. 41: 344–354.
168 Davis, D.R. (1995). Stabilization of RNA stacking by pseudouridine. Nucleic
Acids Res. 23: 5020–5026.
169 Kierzek, E., Malgowska, M., Lisowiec, J. et al. (2014). The contribution of pseu-
douridine to stabilities and structure of RNAs. Nucleic Acids Res. 42: 3492–3501.
170 Davis, F.F. and Allen, F.W. (1957). Ribonucleic acids from yeast which contain
a fth nucleotide. J. Biol. Chem. 227: 907–915.
171 Holley, R.W., Apgar, J., Everett, G.A. et al. (1965). Structure of a ribonucleic
acid. Science 147: 1462–1465.
172 Lane, B.G., Ofengand, J., and Gray, M.W. (1992). Pseudouridine in the
large-subunit (23 S-like) ribosomal RNA. The site of peptidyl transfer in the
ribosome? FEBS Lett. 302: 1–4.
173 Bakin, A. and Ofengand, J. (1993). Four newly located pseudouridylate residues
in Escherichia coli 23S ribosomal RNA are all at the peptidyltransferase center:
analysis by the application of a new sequencing technique. Biochemistry 32:
9754–9762.
174 Khoddami, V., Yerra, A., Mosbruger, T.L. et al. (2019). Transcriptome-wide pro-
ling of multiple RNA modications simultaneously at single-base resolution.
Proc. Natl. Acad. Sci. 116: 6784–6789.
175 Li, X., Zhu, P. , Ma, S. et al. (2015). Chemical pulldown reveals dynamic pseu-
douridylation of the mammalian transcriptome. Nat. Chem. Biol. 11: 592–597.
176 Eyler, D.E., Franco, M.K., Batool, Z. et al. (2019). Pseudouridinylation of mRNA
coding sequences alters translation. PNAS 116: 23068–23074.
177 Adachi, H. and Yu, Y.T. (2020). Pseudouridine-mediated stop codon
readthrough in S. cerevisiae is sequence context-independent. RNA 26:
1247–1256.
178 Karijolich, J. and Yu, Y.-T. (2011). Converting nonsense codons into sense
codons by targeted pseudouridylation. Nature 474: 395–398.
179 Levi, O. and Arava, Y.S. (2021). Pseudouridine-mediated translation control
of mRNA by methionine aminoacyl tRNA synthetase. Nucleic Acids Res. 49:
432–443.
180 Karikó, K., Muramatsu, H., Welsh, F.A. et al. (2008). Incorporation of pseu-
douridine into mRNA yields superior nonimmunogenic vector with increased
translational capacity and biological stability. Mol. Ther. 16: 1833–1840.
References 347
https://t.me/med1917
181 Martinez, N.M., Su, A., Burns, M.C. et al. (2022). Pseudouridine synthases mod-
ify human pre-mRNA co-transcriptionally and aect pre-mRNA processing.
Mol. Cell 82: 645–659.e649.
182 Hamma, T. and Ferré-D’Amaré, A.R. (2006). Pseudouridine synthases. Chem.
Biol. 13: 1125–1135.
183 Liu, B., Zhang, J., Huang, C., and Liu, H. (2012). Dyskerin overexpression in
human hepatocellular carcinoma is associated with advanced clinical stage and
poor patient prognosis. PLoS One 7: e43147.
184 Montanaro, L., Brigotti, M., Clohessy, J. et al. (2006). Dyskerin expression inu-
ences the level of ribosomal RNA pseudo-uridylation and telomerase RNA component in human breast cancer. J. Pathol. 210: 10–18.
185 Bykhovskaya, Y. , Casas, K., Mengesha, E. et al. (2004). Missense mutation in
pseudouridine synthase 1 (PUS1) causes mitochondrial myopathy and sideroblastic anemia (MLASA). Am. J. Human Genet. 74: 1303–1308.
186 Patton, J.R., Bykhovskaya, Y., Mengesha, E. et al. (2005). Mitochondrial
myopathy and sideroblastic anemia (MLASA): missense mutation in the
pseudouridine synthase 1 (PUS1) gene is associated with the loss of tRNA
pseudouridylation. J. Biol. Chem. 280: 19823–19828.
187 Han, S.T., Kim, A.C., Garcia, K. et al. (2022). PUS7 deciency in human
patients causes profound neurodevelopmental phenotype by dysregulating
protein translation. Mol. Genet. Metab. 135: 221–229.
188 Shaheen, R., Tasak, M., Maddirevula, S. et al. (2019). PUS7 mutations impair
pseudouridylation in humans and cause intellectual disability and microcephaly. Hum. Genet. 138: 231–239.
189 Shaheen, R., Han, L., Faqeih, E. et al. (2016). A homozygous truncating muta-
tion in PUS3 expands the role of tRNA modication in normal cognition. Hum.
Genet. 135: 707–713.
190 Zhao, Y., Karijolich, J., Glaunsinger, B., and Zhou, Q. (2016). Pseudouridylation
of 7SK snRNA promotes 7SK snRNP formation to suppress HIV-1 transcription
and escape from latency. EMBO Rep. 17: 1441–1451.
191 Heiss, N.S., Knight, S.W., Vulliamy, T.J. et al. (1998). X-linked dyskeratosis con-
genita is caused by mutations in a highly conserved gene with putative nucleolar functions. Nat. Genet. 19: 32–38.
192 Cui, Q., Yin, K., Zhang, X. et al. (2021). Targeting PUS7 suppresses tRNA pseu-
douridylation and glioblastoma tumorigenesis. Nat. Cancer 2: 932–949.
193 Purchal, M.K., Eyler, D.E., Tardu, M. et al. (2022). Pseudouridine synthase 7
is an opportunistic enzyme that binds and modies substrates with diverse
sequences and structures. Proc. Natl. Acad. Sci. 119: e2109708119.
194 Andries, O., Caerty, S.M., De Smedt, S.C. et al. (2015).
N(1)-methylpseudouridine-incorporated mRNA outperforms
pseudouridine-incorporated mRNA by providing enhanced protein expression
and reduced immunogenicity in mammalian cell lines and mice. J. Controlled
Release 217: 337–344.
348 12 Drugging the Epitranscriptome
https://t.me/med1917
195 Mauger, D.M., Cabral, B.J., Presnyak, V. et al. (2019). mRNA structure reg-
ulates protein expression through changes in functional half-life. PNAS 116:
24075–24083.
196 Anderson, B.R., Muramatsu, H., Nallagatla, S.R. et al. (2010). Incorporation of
pseudouridine into mRNA enhances translation by diminishing PKR activation.
Nucleic Acids Res. 38: 5884–5892.
197 Svitkin, Y.V., Cheng, Y.M., Chakraborty, T. et al. (2017).
N1-methyl-pseudouridine in mRNA enhances translation through
eIF2α-dependent and independent mechanisms by increasing ribosome density.
Nucleic Acids Res. 45: 6023–6036.
198 Nance, K.D. and Meier, J.L. (2021). Modications in an emergency: the role of
N1-Methylpseudouridine in COVID-19 vaccines. ACS Cent. Sci. 7: 748–756.
199 Morais, P., Adachi, H., and Yu, Y.-T. (2021). The critical contribution of pseu-
douridine to mRNA COVID-19 vaccines. Front. Cell Dev. Biol. 9.
200 Morse, D.P. and Bass, B.L. (1997). Detection of inosine in messenger RNA by
inosine-specic cleavage. Biochemistry 36: 8429–8434.
201 Li, J.B., Levanon, E.Y., Yoon, J.K. et al. (2009). Genome-wide identication of
human RNA editing sites by parallel DNA capturing and sequencing. Science
324: 1210–1213.
202 Levanon, E.Y., Eisenberg, E., Yelin, R. et al. (2004). Systematic identication of
abundant A-to-I editing sites in the human transcriptome. Nat. Biotechnol. 22:
1001–1005.
203 Gabay, O., Shoshan, Y., Kopel, E. et al. (2022). Landscape of
adenosine-to-inosine RNA recoding across human tissues. Nat. Commun. 13:
1184.
204 Morita, Y., Shibutani, T., Nakanishi, N. et al. (2013). Human endonuclease V is
a ribonuclease specic for inosine-containing RNA. Nat. Commun. 4: 2273.
205 Sakurai, M., Ueda, H., Yano, T. et al. (2014). A biochemical landscape of A-to-I
RNA editing in the human brain transcriptome. Genome Res. 24: 522–534.
206 Bahn, J.H., Lee, J.H., Li, G. et al. (2012). Accurate identication of A-to-I RNA
editing in human by transcriptome sequencing. Genome Res. 22: 142–150.
207 Peng, Z., Cheng, Y., Tan, B.C.M. et al. (2012). Comprehensive analysis of
RNA-Seq data reveals extensive RNA editing in a human transcriptome. Nat.
Biotechnol. 30: 253–260.
208 Bazak, L., Haviv, A., Barak, M. et al. (2014). A-to-I RNA editing occurs at
over a hundred million genomic sites, located in a majority of human genes.
Genome Res. 24: 365–376.
209 Maas, S., Patt, S., Schrey, M., and Rich, A. (2001). Underediting of glutamate
receptor GluR-B mRNA in malignant gliomas. PNAS 98: 14687–14692.
210 Higuchi, M., Single, F.N., Köhler, M. et al. (1993). RNA editing of AMPA recep-
tor subunit GluR-B: a base-paired intron-exon structure determines position
and eciency. Cell 75: 1361–1370.
211 Rueter, S.M., Burns, C.M., Coode, S.A. et al. (1995). Glutamate receptor RNA
editing in vitro by enzymatic conversion of adenosine to inosine. Science 267:
1491–1494.
References 349
https://t.me/med1917
212 Yang, J.H., Sklar, P., Axel, R., and Maniatis, T. (1995). Editing of glutamate
receptor subunit B pre-mRNA in vitro by site-specic deamination of adenosine. Nature 374: 77–81.
213 Sommer, B., Köhler, M., Sprengel, R., and Seeburg, P.H. (1991). RNA editing in
braincontrolsadeterminantofionow in glutamate-gated channels. Cell 67:
11–19.
214 Brusa, R., Zimmermann, F., Koh, D.S. et al. (1995). Early-onset epilepsy and
postnatal lethality associated with an editing-decient GluR-B allele in mice.
Science 270: 1677–1680.
215 Feldmeyer, D., Kask, K., Brusa, R. et al. (1999). Neurological dysfunctions
in mice expressing dierent levels of the Q/R site-unedited AMPAR subunit
GluR-B. Nat. Neurosci. 2: 57–64.
216 Burns, C.M., Chu, H., Rueter, S.M. et al. (1997). Regulation of serotonin-2C
receptor G-protein coupling by RNA editing. Nature 387: 303–308.
217 Alonso-Andrés, P., Albasanz, J.L., Ferrer, I., and Martín, M. (2018).
Purine-related metabolites and their converting enzymes are altered in frontal,
parietal and temporal cortex at early stages of Alzheimer’s disease pathology.
Brain Pathol. 28: 933–946.
218 Basile, M.S., Bramanti, P. , and Mazzon, E. (2022). Inosine in neurodegenerative
diseases: from the bench to the bedside. Molecules 27.
219 Gurevich, I., Tamir, H., Arango, V. et al. (2002). Altered editing of serotonin
2C receptor pre-mRNA in the prefrontal cortex of depressed suicide victims.
Neuron 34: 349–356.
220 Lotsof, E.R., Krajewski, A.E., Anderson-Steele, B. et al. (2022). NEIL1 recoding
due to RNA editing impacts lesion-specic recognition and excision. JACS 144:
14578–14589.
221 Yeo, J., Goodman, R.A., Schirle, N.T. et al. (2010). RNA editing changes the
lesion specicity for the DNA repair enzyme NEIL1. Proc. Natl. Acad. Sci. 107:
20715–20719.
222 Jain, M., Manjaly, G., Maly, K. et al. (2022). Filamin a pre-mRNA editing mod-
ulates vascularization and tumor growth. Mol. Ther. Nucleic Acids 30: 522–534.
223 Jain, M., Mann, T.D., Stuli´c, M. et al. (2018). RNA editing of lamin a
pre-mRNA regulates vascular contraction and diastolic blood pressure. Embo J.
37.
224 Rafels-Ybern, À., Torres, A.G., Camacho, N. et al. (2018). The expansion of
inosine at the wobble position of tRNAs, and its role in the evolution of proteomes. Mol. Biol. Evol. 36: 650–662.
225 Diaz Quiroz, J.F., Siskel, L.D., and Rosenthal, J.J.C. (2023). Site-directed A → I
RNA editing as a therapeutic tool: moving beyond genetic mutations. RNA 29:
498–505.
226 Kato, H., Takeuchi, O., Sato, S. et al. (2006). Dierential roles of MDA5 and
RIG-I helicases in the recognition of RNA viruses. Nature 441: 101–105.
227 Chung, H., Calis, J.J.A., Wu, X. et al. (2018). Human ADAR1 prevents endoge-
nous RNA from triggering translational shutdown. Cell 172: 811–824.e814.
350 12 Drugging the Epitranscriptome
https://t.me/med1917
228 Liddicoat, B.J., Piskol, R., Chalk, A.M. et al. (2015). RNA editing by ADAR1
prevents MDA5 sensing of endogenous dsRNA as nonself. Science 349:
1115–1120.
229 Hartner, J.C., Schmittwolf, C., Kispert, A. et al. (2004). Liver disintegration in
the mouse embryo caused by deciency in the RNA-editing enzyme ADAR1. J.
Biol. Chem. 279: 4894–4902.
230 Pestal, K., Funk, C.C., Snyder, J.M. et al. (2015). Isoforms of RNA-editing
enzyme ADAR1 independently control nucleic acid sensor MDA5-driven
autoimmunity and multi-organ development. Immunity 43: 933–944.
231 Rice, G.I., Kasher, P.R., Forte, G.M.A. et al. (2012). Mutations in ADAR1 cause
Aicardi-Goutières syndrome associated with a type I interferon signature. Nat.
Genet. 44: 1243–1248.
232 Kung, C.-P., Cottrell, K.A., Ryu, S. et al. (2021). Evaluating the therapeutic
potential of ADAR1 inhibition for triple-negative breast cancer. Oncogene 40:
189–202.
233 Galore-Haskel, G., Nemlich, Y., Greenberg, E. et al. (2015). A novel immune
resistance mechanism of melanoma cells controlled by the ADAR1 enzyme.
Oncotarget 6: 28999–29015.
234 Fritzell, K., Xu, L.D., Lagergren, J., and Öhman, M. (2018). ADARs and editing:
the role of A-to-I RNA modication in cancer progression. Semin. Cell Dev. Biol.
79: 123–130.
235 Gannon, H.S., Zou, T., Kiessling, M.K. et al. (2018). Identication of ADAR1
adenosine deaminase dependency in a subset of cancer cells. Nat. Commun. 9:
5450.
236 Liu, H., Golji, J., Brodeur, L.K. et al. (2019). Tumor-derived IFN triggers
chronic pathway agonism and sensitivity to ADAR loss. Nat. Med. 25: 95–102.
237 Ishizuka, J.J., Manguso, R.T., Cheruiyot, C.K. et al. (2019). Loss of ADAR1 in
tumours overcomes resistance to immune checkpoint blockade. Nature 565:
43–48.
238 Bhate, A., Sun, T., and Li, J.B. (2019). ADAR1: a new target for
immuno-oncology therapy. Mol. Cell 73: 866–868.
239 Cottrell, K.A., Torres, L.S., Dizon, M.G., and Weber, J.D. (2021). 8-Azaadenosine
and 8-chloroadenosine are not selective inhibitors of ADAR. Cancer Res. Com-
mun. 1: 56–64.
240 Wang, X., Li, J., Zhu, Y. et al. (2021). Targeting ADAR1 with a novel
small-molecule for the treatment of prostate cancer. Res. Square https://doi
.org/10.21203/rs.3.rs-879741/v1.
241 Mendoza, H.G., Matos, V.J., Park, S. et al. (2023). Selective inhibition of ADAR1
using 8-azanebularine-modied RNA duplexes. Biochemistry 62: 1376–1387.
242 Crews, L.A., Ma, W., Ladel, L. et al. (2023). Reversal of malignant ADAR1
splice isoform switching with rebecsinib. Cell Stem Cell 30: 250–263.e256.
243 Guimond, D.S., Theodore, Joseph, G. et al. (2022). Gossamer Bio, 27th Annual
Meeting of the RNA Society.
244 Pan, T. (2018). Modications and functional genomics of human transfer RNA.
Cell Res. 28: 395–404.
本书版权归John Wiley & Sons Inc.所有
References 351
https://t.me/med1917
245 Crick, F.H.C. (1966). Codon—anticodon pairing: the wobble hypothesis. J. Mol.
Biol. 19: 548–555.
246 Lorenz, C., Lünse, C.E., and Mörl, M. (2017). tRNA modications: impact on
structure and thermal adaptation. Biomolecules 7: 35.
247 Han, L. and Phizicky, E.M. (2018). A rationale for tRNA modication circuits
in the anticodon loop. RNA 24: 1277–1284.
248 Motorin, Y. and Helm, M. (2010). tRNA stabilization by modied nucleotides.
Biochemistry 49: 4934–4944.
249 Brégeon, D., Pecqueur, L., Toubdji, S. et al. (2022). Dihydrouridine in the tran-
scriptome: new life for this ancient RNA chemical modication. ACS Chem.
Biol. 17: 1638–1657.
250 Muramatsu, T., Yokoyama, S., Horie, N. et al. (1988). A novel lysine-substituted
nucleoside in the rst position of the anticodon of minor isoleucine tRNA from
Escherichia coli. J. Biol. Chem. 263: 9261–9267.
251 Moshitch-Moshkovitz, S., Dominissini, D., and Rechavi, G. (2022). The epitran-
scriptome toolbox. Cell 185: 764–776.
252 Li, X., Xiong, X., and Yi, C. (2017). Epitranscriptome sequencing technologies:
decoding RNA modications. Nat. Methods 14: 23–31.
253 Jain, M., Abu-Shumays, R., Olsen, H.E., and Akeson, M. (2022). Advances in
nanopore direct RNA sequencing. Nat. Methods 19: 1160–1164.
254 Pratanwanich, P.N., Yao , F., Chen, Y. et al. (2021). Identication of dierential
RNA modications from nanopore direct RNA sequencing with xPore. Nat.
Biotechnol. 39: 1394–1402.
255 Workman, R.E., Tang, A.D., Tang, P.S. et al. (2019). Nanopore native RNA
sequencing of a human poly(A) transcriptome. Nat. Methods 16: 1297–1305.
256 Begik, O., Lucas, M.C., Pryszcz, L.P. et al. (2021). Quantitative proling of
pseudouridylation dynamics in native RNAs with nanopore sequencing. Nat.
Biotechnol. 39: 1278–1291.
257 Liu, H., Begik, O., Lucas, M.C. et al. (2019). Accurate detection of m
6
ARNA
modications in native RNA sequences. Nat. Commun. 10: 4079.
258 Leger, A., Amaral, P. P., Pandolni, L. et al. (2021). RNA modications detection
by comparative nanopore direct RNA sequencing. Nat. Commun. 12: 7198.
259 Su, D., Chan, C.T.Y., Gu, C. et al. (2014). Quantitative analysis of ribonucleo-
side modications in tRNA by HPLC-coupled mass spectrometry. Nat. Protoc. 9:
828–841.
260 Gu, C., Begley, T.J., and Dedon, P.C. (2014). tRNA modications regulate trans-
lation during cellular stress. FEBS Lett. 588: 4287–4296.
261 Chan, C.T., Pang, Y.L.J., Deng, W. et al. (2012). Reprogramming of tRNA mod-
ications controls the oxidative stress response by codon-biased translation of
proteins. Nat. Commun. 3: 937.
262 Candiracci, J., Migeot, V., Chionh, Y.H. et al. (2019). Reciprocal regula-
tion of TORC signaling and tRNA modications by elongator enforces
nutrient-dependent cell fate. Sci. Adv. 5: eaav0184.
352 12 Drugging the Epitranscriptome
https://t.me/med1917
263 Keam, S.P. and Hutvagner, G. (2015). tRNA-derived fragments (tRFs): emerg-
ing new roles for an ancient RNA in the regulation of gene expression. Life 5:
1638–1651.
264 Krishna, S., Raghavan, S., DasGupta, R., and Palakodeti, D. (2021).
tRNA-derived fragments (tRFs): establishing their turf in post-transcriptional
gene regulation. Cell. Mol. Life Sci. 78: 2607–2619.
265 Zhu, L., Ge, J., Li, T. et al. (2019). tRNA-derived fragments and tRNA halves:
the new players in cancers. Cancer Lett. 452: 31–37.
266 Wang, Y., Tao, E.W., Tan, J. et al. tRNA modications: insights into their role in
human cancers. Trends Cell Biol.
267 Scharath, R. and Leidel, S.A. (2017). Wobble uridine modications-a reason to
live, a reason to die?! RNA Biol. 14: 1209–1222.
268 Rapino, F., Delaunay, S., Rambow, F. et al. (2018). Codon-specic translation
reprogramming promotes resistance to targeted therapy. Nature 558: 605–609.
269 Nedialkova, D.D. and Leidel, S.A. (2015). Optimization of codon translation
rates via tRNA modications maintains proteome integrity. Cell 161: 1606–1618.
270 Delaunay, S., Rapino, F., Tharun, L. et al. (2016). Elp3 links tRNA modication
to IRES-dependent translation of LEF1 to sustain metastasis in breast cancer. J.
Exp. Med. 213: 2503–2523.
271 Katsara, O. and Schneider, R.J. (2021). m7G tRNA modication reveals new
secrets in the translational regulation of cancer development. Mol. Cell 81:
3243–3245.
272 Orellana, E.A., Liu, Q., Yankova, E. et al. (2021). METTL1-mediated m7G
modication of Arg-TCT tRNA drives oncogenic transformation. Mol. Cell 81:
3323–3338.e3314.
273 Dai, Z., Liu, H., Liao, J. et al. (2021). N7-Methylguanosine tRNA modication
enhances oncogenic mRNA translation and promotes intrahepatic cholangiocarcinoma progression. Mol. Cell 81: 3339–3355.e3338.
274 Blaesius, K., Abbasi, A.A., Tahir, T.H. et al. (2018). Mutations in the tRNA
methyltransferase 1 gene TRMT1 cause congenital microcephaly, isolated inferior vermian hypoplasia and cystic leukomalacia in addition to intellectual
disability. Am. J. Med. Genet. A 176: 2517–2521.
275 Dewe, J.M., Fuller, B.L., Lentini, J.M. et al. (2017). TRMT1-catalyzed tRNA
modications are required for redox homeostasis to ensure proper cellular
proliferation and oxidative stress survival. Mol. Cell. Biol. 37.
276 Lin, S., Liu, Q., Lelyveld, V.S. et al. (2018). Mettl1/Wdr4-mediated m(7)G tRNA
methylome is required for normal mRNA translation and embryonic stem cell
self-renewal and dierentiation. Mol. Cell 71: 244–255.e245.
277 Suzuki, T., Yashiro, Y., Kikuchi, I. et al. (2020). Complete chemical structures of
human mitochondrial tRNAs. Nat. Commun. 11: 4269.
278 Asano, K., Suzuki, T., Saito, A. et al. (2018). Metabolic and chemical regulation
of tRNA modication associated with taurine deciency and human disease.
Nucleic Acids Res. 46: 1565–1583.
279 Morscher, R.J., Ducker, G.S., Li, S.H.J. et al. (2018). Mitochondrial translation
requires folate-dependent tRNA methylation. Nature 554: 128–132.
References 353
https://t.me/med1917
280 Becker, L., Kling, E., Schiller, E. et al. (2014). MTO1-decient mouse model
mirrors the human phenotype showing complex I defect and cardiomyopathy.
PLoS One 9: e114918.
281 Rikimaru, M., Ohsawa, Y., Wolf, A.M. et al. (2012). Taurine ameliorates
impaired the mitochondrial function and prevents stroke-like episodes in
patients with MELAS. Intern. Med. 51: 3351–3357.
282 Ohsawa, Y. , Hagiwara, H., Nishimatsu, S. et al. (2019). Taurine supplementation
for prevention of stroke-like episodes in MELAS: a multicentre, open-label,
52-week phase III trial. J. Neurol. Neurosurg. Psychiatry 90: 529–536.
283 Bacman, S.R., Williams, S.L., Pinto, M. et al. (2013). Specic elimination of
mutant mitochondrial genomes in patient-derived cells by mitoTALENs. Nat.
Med. 19: 1111–1113.
284 Ciara Ann, A., Penelope Nicole, H., and Peter, T. (2018). MERRF and MELAS:
current gene therapy trends and approaches. 2: 9.
285 Velez-Bartolomei, F., Lee, C., and Enns, G. MERRF. GeneReviews.
286 Sloan, K.E., Warda, A.S., Sharma, S. et al. (2017). Tuning the ribosome: the
inuence of rRNA modication on eukaryotic ribosome biogenesis and function. RNA Biol. 14: 1138–1152.
287 Babaian, A., Rothe, K., Girodat, D. et al. (2020). Loss of m1acp3Ψ ribosomal
RNA modication is a major feature of cancer. Cell Rep. 31: 107611.
288 Armistead, J., Khatkar, S., Meyer, B. et al. (2009). Mutation of a gene essen-
tial for ribosome biogenesis, EMG1, causes Bowen-Conradi syndrome. Am. J.
Human Genet. 84: 728–739.
289 Doll, A. and Grzeschik, K.-H. (2001). Characterization of two novel genes,
WBSCR20 and WBSCR22, deleted in Williams-Beuren syndrome. Cytogenet. Cell
Genet. 95: 20–27.
290 Cowling, V.H., Turner, S.A., and Cole, M.D. (2014). Burkitt’s
lymphoma-associated c-Myc mutations converge on a dramatically altered
target gene response and implicate Nol5a/Nop56 in oncogenesis. Oncogene 33:
3519–3527.
291 Ito, A., Watabe, K., Koma, Y. et al. (2001). Increased expression of a nucleolar
Nop5/Sik family member in metastatic melanoma cells: evidence for its role in
nucleolar sizing and function. Am. J. Pathol. 159: 1363–1374.
292 Williams, G.T. and Farzaneh, F. (2012). Are snoRNAs and snoRNA host genes
new players in cancer? Nat. Rev. Cancer 12: 84–88.
293 Mannoor, K., Liao, J., and Jiang, F. (2012). Small nucleolar RNAs in cancer.
Biochim. Biophys. Acta 1826: 121–128.
294 Ruggero, D., Grisendi, S., Piazza, F. et al. (2003). Dyskeratosis congenita and
cancer in mice decient in ribosomal RNA modication. Science 299: 259–262.
295 Marcel, V., Ghayad, S.E., Belin, S. et al. (2013). p53 acts as a safeguard of
translational control by regulating brillarin and rRNA methylation in cancer.
Cancer Cell 24: 318–330.
296 Catez, F., Venezia, N.D., Marcel, V. et al. (2019). Ribosome biogenesis: an
emerging druggable pathway for cancer therapeutics. Biochem. Pharmacol. 159:
74–81.
354 12 Drugging the Epitranscriptome
https://t.me/med1917
297 Drygin, D., Lin, A., Bliesath, J. et al. (2011). Targeting RNA polymerase I with
an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid
tumor growth. Cancer Res. 71: 1418–1430.
298 Lucas, M.C., Pryszcz, L.P., Medina, R. et al. (2023). Quantitative analysis
of tRNA abundance and modications by nanopore RNA sequencing. Nat.
Biotechnol. 1–15.
299 Liu, C., Sun, H., Yi, Y. et al. (2023). Absolute quantication of single-base
m(6)A methylation in the mammalian transcriptome using GLORI. Nat.
Biotechnol. 41: 355–366.
300 Dai, W., Li, A., Yu, N.J. et al. (2021). Activity-based RNA-modifying enzyme
probing reveals DUS3L-mediated dihydrouridylation. Nat. Chem. Biol.
Соседние файлы в папке Библиотека им академика М.И. Перельмана